Abstract
Gene therapy orphan medicinal products constitute a unique group of new drugs which in case of hereditary diseases are usually administered only once at an early age, in the hope to provide sufficient gene product to last for the entire life of the patients. The combination of an exceptionally large single payment and the life-long clinical follow-up needed for understanding the long-term benefits and safety of gene therapy, represent new types of scientific, financial, social and ethical challenges for the pharmaceutical industry, regulators and society. With special consideration of the uniqueness and importance of gene therapy, the authors propose a three points plan for a close cooperation between the pharmaceutical industry and society to develop orphan gene therapy. (1) In fully transparent health technology negotiations a close and long-lasting, contractually fixed cooperation should be established between the manufacturers and local health-care stakeholders for sharing the medical and scientific benefits, the financial risks as well as the burdens of the post-authorization clinical and regulatory development. (2) The parties should agree on a fair, locally affordable drug price without the usually very high premium price calculated to compensate for the low number of patients. In case of high manufacturing costs, the companies should offer prolonged, 15–20 years long payment by installment with risk-sharing, especially considering that the late outcome of the treatment is unknown. Society should assist scientifically and financially organizing a specific patient registry, treatment in specialized hospitals and adequate long-term follow-up of patients, the coordinated management of financial transactions related to the risk sharing program. (3) The post-authorization treatment and prolonged observation of additional new cases coordinated by society should provide real world data needed for the modern complex regulatory evaluation of gene therapy products by the competent authorities. We assume that fair sharing of the benefits and risks as well as a well-organized cooperation of society with the industry in collecting real world evidence might result in better drug evaluation and improved accessibility due to lower prices. The outlined concept might support gene therapy more efficiently than the presently requested outstandingly high prices.
Highlights
The Orphan Drug Act accepted in 1983 in the United States of America (US) introduced officially the concept of rare diseases and the corresponding orphan drug designation to stimulate drug development in this area [1]
A frequently asked question is how far society can cover the upward pricing spiral elicited by new types of drugs, primarily by gene therapy products
The generally over-optimistic hope of the parents led to surprising approaches to secure Zolgensma R for their seriously sick children in countries where the drug was not yet marketed
Summary
The Orphan Drug Act accepted in 1983 in the United States of America (US) introduced officially the concept of rare diseases and the corresponding orphan drug designation to stimulate drug development in this area [1]. A successful solution must effectively limit their outstandingly high costs while it should ensure their faster and improving clinical and regulatory development in a broader cooperation with society These problems will be discussed using as an example the treatment of spinal muscular atrophy (SMA) with the recently introduced gene therapy product Onasemnogene abeparvovec (Zolgensma R ). Some of the data on pricing and cost-effectiveness of Zolgensma R generated in the US will be used for the discussion due to their abundant and reliable documentation Based on this example we shall propose a new type of lasting contractual cooperation between the manufacturers and society for sharing the benefits as well as the financial and scientific burdens of the clinical and regulatory development of advanced orphan gene therapy products. We wish to emphasize that our intention is to discuss the general problems related to the pricing of gene therapies rather than to criticize the specific marketing strategy of one medicinal product
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
